Maddi Hebebrand, MC, Associate Editor

Clinuvel's phase III trial CUV105 enrolls 200 patients, exploring afamelanotide as a promising systemic treatment for vitiligo.

Discover how a novel nutraceutical significantly improves mild to moderate acne in a 12-week clinical trial, offering a holistic approach to skin health.

Explore the promising role of JAK inhibitors in vitiligo management, highlighting efficacy, safety, and potential combination therapies for enhanced results.

Explore the critical need for diversity in hidradenitis suppurativa clinical trials to address health inequities and improve patient outcomes.

Discover an innovative non-surgical keloid treatment protocol that achieves high satisfaction and low recurrence rates for patients with darker skin tones.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Johnson & Johnson's icotrokinra shows promising results in treating moderate plaque psoriasis, especially in challenging areas like the scalp and genitals.

Recent analysis reveals abrocitinib's long-term safety in atopic dermatitis, highlighting age-related risks and the importance of tailored dosing for older patients.

FDA accelerates AI integration by 2025, enhancing scientific reviews and modernizing regulatory processes for improved public health outcomes.

The Clinical Image Collection enhances dermatologic education by providing diverse images of skin conditions, promoting inclusivity and accurate diagnoses across all skin tones.

Roflumilast foam shows significant efficacy in treating scalp and body psoriasis, enhancing patient adherence and quality of life in a recent clinical trial.

Explore the hidden health risks of nail products and the urgent need for safety reforms in the nail salon industry for workers and customers alike.

Delgocitinib cream significantly enhances health-related quality of life for patients with chronic hand eczema, addressing both symptoms and psychosocial impacts.

MJH Life Sciences acquires NewBeauty, merging clinical expertise with consumer-driven wellness to redefine beauty and aesthetics media.

Peter Lio, MD, discusses innovative treatments for pediatric atopic dermatitis, including microbiome therapies and botanical options.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Guselkumab shows high effectiveness and safety in treating moderate to severe plaque psoriasis, enhancing quality of life in real-world Korean patients.

Explore the urgent need for sustainability in dermatology, addressing its environmental impact and advocating for eco-friendly practices in health care.

Acoustic stimulation using infrasound and low-frequency sound enhances wound healing, promoting cellular activity and tissue repair in innovative, non-invasive ways.

New research reveals JAK inhibitors for atopic dermatitis do not increase cardiovascular or cancer risks compared to IL-4/-13 inhibitors, offering reassurance for patients.

Explore the top headlines of the week including insights on recalls, expert pearls, and more.

The FDA approved pz-cel, a groundbreaking gene therapy for recessive dystrophic epidermolysis bullosa, transforming treatment options for patients.

JAK inhibitors show promise in treating alopecia areata among Black patients, highlighting the need for inclusive clinical research and equitable access to therapies.

Discover cutting-edge insights on atopic dermatitis at RAD 2025, featuring expert discussions and the latest therapies to enhance your practice.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.